Kiox Pharmaceuticals ApS: Financial statements 2025
CVR: 42886866
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Kiox Pharmaceuticals ApS (CVR 42886866) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 120,473 and a net result of DKK -639,537 compared with DKK -1,841,030 the year before. Equity in the 2025 report amounted to DKK -404,366.
- Gross Profit
- DKK 120,473
- Profit/Loss
- DKK -639,537
- Equity
- DKK -404,366
- Total Assets
- DKK 1,155,074
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 120 t. | -640 t. | -404 t. | - |
| 2024 | - | -412 t. | -1.8 mio. | 235 t. | - |
| 2023 | - | 412 t. | -969 t. | -64 t. | - |
| 2022 | - | -3 t. | -3 t. | 37 t. | - |
Official annual report
How creditworthy is Kiox Pharmaceuticals ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Kiox Pharmaceuticals ApS has published its annual report for 2024. Gross profit came to DKK -411,764, and the net result was DKK -1,841,030.
About Kiox Pharmaceuticals ApS
Kiox Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in Snekkersten, founded in 2021. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Mikkel Walmar and Tim Dehli Carstensen. The board consists of Mikkel Walmar (chair), Inge Tarnow and Lars Hellerung Christiansen. The company is owned by HELLERUNG ApS, Titi14 HOLDING ApS and 26c Holding ApS. In 2025, the company reported a gross profit of DKK 120,473 and a net result of DKK -639,537 compared with DKK -1,841,030 the year before. Equity in the 2025 report amounted to DKK -404,366.